Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall

Atherosclerosis

Volumn 206, Issue 2, 2009, Pages 505-511

  Kajimoto, Kan ^a   Miyauchi, Katsumi ^a   Kasai, Takatoshi ^a   Shimada, Kazunori ^a   Kojima, Yuko ^b   Shimada, Akie ^a   Niinami, Hiroshi ^a   Amano, Atsushi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Abdominal aortic aneurysm; Atherosclerosis; c Jun N terminal kinase; HMG CoA reductase inhibitor; Inflammation; Vascular dendritic cells

Indexed keywords

ATORVASTATIN; GELATINASE A; GELATINASE B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; STRESS ACTIVATED PROTEIN KINASE;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; AORTA RECONSTRUCTION; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; T LYMPHOCYTE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AORTIC ANEURYSM, ABDOMINAL; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PYRROLES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 70349410381     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.03.028     Document Type: Article

References (20)

1. Yoshimura K., Aoki H., Ikeda Y., et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 11 12 (2005) 1330-1338
2. Ranjit S., and Dazhu L. Potential role of dendritic cells for progression of atherosclerotic lesions. Postgrad Med J 82 971 (2006) 573-575
3. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 7 (2001) 926-933
4. Sumara G., Belwal M., and Ricci R. "Jnking" atherosclerosis. Cell Mol Life Sci 62 21 (2005) 2487-2494
5. Tsujimoto A., Takemura G., Mikami A., et al. A therapeutic dose of the lipophilic statin pitavastatin enhances oxidant-induced apoptosis in human vascular smooth muscle cells. J Cardiovasc Pharmacol 48 4 (2006) 160-165
6. Van Vré E.A., Hoymans V.Y., Bult H., et al. Decreased number of circulating plasmacytoid dendritic cells in patients with atherosclerotic coronary artery disease. Coron Artery Dis 17 3 (2006) 243-248
7. Bobryshev Y.V. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 26 17 (2005) 1700-1704 [Epub 2005 Apr 26]
8. Yilmaz A., Lochno M., Traeg F., et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 176 (2004) 101-110
9. Yilmaz A., Reiss C., Tantawi O., et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172 (2004) 85-93
10. Wilson W.R., Anderton M., Schwalbe E.C., et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 113 3 (2006) 438-445
11. Nishimura K., Ikebuchi M., Kanaoka Y., et al. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms. Int Angiol 22 3 (2003) 229-238
12. Liang S.L., Liu H., and Zhou A. Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. J Immunol 177 1 (2006) 651-656
13. Sampieri C.L., Nuttall R.K., Young D.A., et al. Activation of p38 and JNK MAPK pathways abrogates requirement for new protein synthesis for phorbol ester mediated induction of select MMP and TIMP genes. Matrix Biol October 4 (2007) [Epub ahead of print]
14. Nagashima H., Aoka Y., Sakomura Y., et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 36 1 (2002) 158-163
15. Yoshida M. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb 10 3 (2003) 140-144
16. de Lemos J.A., Morrow D.A., Blazing M.A., et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 50 22 (2007) 2117-2124 [Epub 2007 Nov 13]
17. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 8 (2005) 1405-1410
18. Blazing M.A., De Lemos J.A., Dyke C.K., et al. The A-to-Z Trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 142 2 (2001) 211-217
19. Rosenson R.S. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 1 6 (2001) 411-420
20. Blair E. Gold is not always good enough: the shortcomings of randomization when evaluating interventions in small heterogeneous samples. J Clin Epidemiol 57 12 (2004) 1219-1222